GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » 5-Year EBITDA Growth Rate

KAPA (Kairos Pharma) 5-Year EBITDA Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kairos Pharma 5-Year EBITDA Growth Rate?

Kairos Pharma's EBITDA per Share for the three months ended in Dec. 2024 was $-0.07.

During the past 3 years, the average EBITDA Per Share Growth Rate was -4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kairos Pharma was -4.40% per year. The lowest was -14.30% per year. And the median was -9.35% per year.


Competitive Comparison of Kairos Pharma's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Kairos Pharma's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kairos Pharma's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kairos Pharma's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Kairos Pharma's 5-Year EBITDA Growth Rate falls into.


;
;

Kairos Pharma 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Kairos Pharma  (AMEX:KAPA) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Kairos Pharma 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Kairos Pharma's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Kairos Pharma Business Description

Traded in Other Exchanges
N/A
Address
2355 Westwood Boulevard, 139, Los Angeles, CA, USA, 90064
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.